Suxilepum

Suxilepum – the synthetic anticonvulsant drug used at treatment of small epileptic seizures at adults and children.

Pharmacological action of Suxilepum

Active component of Suxilepum has anticonvulsant effect.

As a result of use of Suxilepum the threshold of developing of epileptic seizures raises that is connected with process of oppression of synoptic transfer in motor zones of a cerebral cortex.

Besides, at an epileptiform neuralgia Suxilepum according to the instruction has the expressed analgeziruyushchy effect.

Release form

The drug Suxilepum is produced in the form of the capsules, white with an orange lid, containing 250 mg of active ingredient – an Ethosuximidum (in the form of the white hardened weight).

Excipients – dye yellow, a macrogoal 400, gelatin, titanium dioxide and the water purified. In bottles on 100 and 120 pieces.

Suxilepum analogs on active ingredient are not released.

Indications to use of Suxilepum

Suxilepum according to the instruction is appointed for treatment of small epileptic seizures at:

• Piknoleptichesky absentias epileptica, including difficult or atypical convulsive attacks;
• Juvenile myoclonic attacks;
• Miokloniko-astatichesky small attacks.

Contraindications

According to the instruction it is contraindicated to accept Suxilepum at:

• Porphyrias;
• Blood diseases;
• Abnormal liver functions and kidneys;
• Pregnancies and in the period of a lactation;
• Hypersensitivity to Suxilepum components.

It is necessary to be careful at treatment by Suxilepum of patients with disturbance of mentality in the anamnesis not to provoke development of such side effects as hallucinatory symptoms and alarming states.

During treatment by the drug Suxilepum it is not necessary to take alcoholic beverages.

Suxilepum route of administration

The daily dosage of Suxilepum according to the instruction is calculated and adjusted individually by the doctor proceeding from a clinical picture of a disease, body weight, efficiency of the carried-out therapy and portability of drug.

As a rule, for adults and children the daily dose of Suxilepum in an initiation of treatment makes 5-10 mg/kg of body weight. Gradually, is not more often than two weekly, it is increased if necessary by 5 mg/kg.

The daily dosage of the supporting treatment by Suxilepum according to reviews for adults makes 15 mg/kg, for children – no more than 20 mg/kg of body weight. The most admissible daily dosage should not exceed the maintenance dose increased twice. At non-compliance with the mode of dosing epileptic seizures can renew.

It is according to reviews effective to accept Suxilepum during food or right after it, dividing the daily dosage appointed by the doctor into 2-3 receptions. However in those cases if use of Suxilepum does not cause side effects, drug can be accepted in one step.

To children up to 6 years Suxilepum in capsules is not appointed because of complexity to observe the accuracy of a necessary dosage. For treatment of this age group select the drug containing active component an Ethosuximidum in a liquid dosage form.

Treatment duration according to reviews is established by Suxilepum individually. Usually therapy is carried out it is long, and it includes the period 2-3 years from the moment of disappearance of attacks then gradual cancellation of Suxilepum with gradual decrease in a dosage is possible.

At treatment of children the body weight increasing over time does not demand increase in the accepted Suxilepum doses, however efficiency of therapy needs to be checked the corresponding researches.

Long use of Suxilepum can lead to development of generalized convulsive attacks.

At reception of Suxilepum in the doses considerably exceeding therapeutic the following symptoms can develop:

• Fatigue;
• Loss of interest to surrounding against the background of decrease in physical activity;
• Hyperexcitability;
• Deterioration in mood;
• Irritability.

At use of Suxilepum it is necessary to consider that the concomitant use with some medicines can have negative character. So, at combined use of Suxilepum:

• With carbamazepine – decrease in therapeutic effect of treatment is observed that it is connected with acceleration of removal of an Ethosuximidum from plasma;
• With valproic acid and a haloperidol – metabolism process can change that will lead to increase or decrease in concentration of active component in plasma;
• With the medicinal substances having the oppressing effect on the central nervous system – can lead to strengthening of side effects.

Side effects of Suxilepum

Suxilepum according to reviews can cause side effects which expressiveness depends on the accepted dose. First of all, disturbances from the central nervous system which are shown as concern to them:

• Ataxy;
• Dizziness;
• Headache;
• Unusual fatigue;
• Decrease in concentration of attention;
• Depression;
• Hallucinatory paranoid frustration;
• Dyskinesia;
• Drowsiness;
• Irritability;
• Weakness;
• Aggression;
• Strengthening of toniko-clonic spasms.

Such frustration of the alimentary system as vomiting, nausea, lock or diarrhea, decrease in body weight and loss of appetite also have dozozavisimy character.

These disturbances, as a rule, can be avoided, increasing the accepted Suxilepum dose gradually, and also combining administration of drug with food.

At reception of Suxilepum according to reviews treat other undesirable actions:

• Skin rash, is slightly more rare – development of a syndrome as a system lupus erythematosus (varying severity);
• Eosinophilia, leukopenia, agranulocytosis and thrombocytopenia, at predisposition – a pancytopenia and aplastic anemia;
• Hiccups, photosensitization, parkinsonism, albuminuria.

At emergence of similar symptoms reception of Suxilepum is stopped according to reviews.

At use of Suxilepum symptoms of myelotoxic action – tonsillitis, fever and the raised bleeding in case of which developing it is necessary to inform the attending physician can also develop.

Storage conditions

Suxilepum belongs to anticonvulsant drugs which issue from drugstores is possible according to the medical recipe. The recommended Suxilepum period of storage at a temperature which is not exceeding 25 °C – 5 years.